University of California Irvine School of Medicine

Impact of Data Source for Benchmarking Antibiotic Usage in U.S. Nursing Homes
Dr. Gussin is an infectious diseases epidemiologist and postdoctoral fellow in the Division of Infectious Diseases
at the University of California, Irvine School of Medicine. Her research aims to improve care quality and
outcomes for nursing home residents, with a focus on the epidemiology and prevention of antibiotic-resistant
organisms and infections. Dr. Gussin has conducted infection prevention intervention studies in nursing homes.
Her work integrates diverse data sources, including microbiologic surveillance, clinical data, and genomics, to
understand transmission and outcomes from the microbe to the population level.
Antibiotic stewardship in U.S. nursing homes is a national priority, yet validated and comparable benchmarks
for antibiotic use remain limited due to gaps in existing data sources. Administrative datasets such as the
Minimum Data Set (MDS) provide limited episodic information, whereas electronic health records (EHRs) offer
richer detail but require validation and harmonization for surveillance. This project evaluates the validity,
completeness, and concordance of antibiotic use measures derived from MDS and EHR medication
administration records and examines how data source choice affects resident-level estimates and facility-level
benchmarking. This award will provide Dr. Gussin with the necessary training and experience using the
Long-Term Care (LTC) Data Cooperative EHR data to: (1) Evaluate the validity, completeness, and
concordance of antibiotic use measures derived from MDS and EHR medication administration records, (2)
Quantify differences in antibiotic use estimates (e.g., prevalence, antibiotic course rates, and days of therapy),
(3) Assess variation across resident subgroups (e.g., short vs. long-stay, residents with different chronic
conditions or devices), and (4) Evaluate how data source choice affects facility-level benchmarking. This
project will generate evidence to support public health surveillance by producing benchmarking-relevant
measures for antibiotic use in U.S. nursing homes. Findings will clarify how data source choice influences
facility-level benchmarking and support the development of reusable measures to guide future nursing home
stewardship research and clinical trial planning. This work will lay the foundation for future pragmatic nursing
home studies evaluating infections and antibiotic use, supporting research that improves care and outcomes
for nursing home residents.